Last updated: November 4, 2026
VIOKACE is a niche pancreatic enzyme replacement therapy marketed by AbbVie for exocrine pancreatic insufficiency caused by chronic pancreatitis or pancreatectomy. Its commercial position is materially smaller than AbbVie’s CREON franchise because VIOKACE is an immediate-release pancrelipase product that must be administered with a proton-pump inhibitor. AbbVie does not report VIOKACE revenue separately, so product-level sales, profitability, and revenue growth cannot be established from public filings. The principal commercial drivers are persistent demand for pancreatic enzyme replacement therapy, supply constraints affecting the category, limited therapeutic substitution, and the stronger market position of delayed-release products such as CREON, ZENPEP, PERTZYE, and PANCREAZE.
What is VIOKACE and how does it work?
VIOKACE contains pancrelipase, a porcine-derived mixture of lipase, protease, and amylase enzymes. It is approved in three tablet strengths based on lipase activity:
| Product strength |
Lipase content |
Form |
| VIOKACE 10,440 |
10,440 USP units |
Tablet |
| VIOKACE 20,880 |
20,880 USP units |
Tablet |
| VIOKACE 41,760 |
41,760 USP units |
Tablet |
VIOKACE is indicated for adults with exocrine pancreatic insufficiency resulting from chronic pancreatitis or pancreatectomy. Unlike enteric-coated pancreatic enzyme products, VIOKACE tablets are not designed to resist gastric acid. The FDA label therefore requires concurrent administration with a proton-pump inhibitor to reduce acid-mediated enzyme degradation and improve delivery to the small intestine (U.S. Food and Drug Administration [FDA], 2023).
This administration requirement limits VIOKACE’s convenience relative to delayed-release capsules. It also creates a separate prescription and monitoring burden, particularly for patients already receiving complex gastrointestinal or oncology-related care.
What is the FDA regulatory status of VIOKACE?
VIOKACE was approved under NDA 022210. The product is an FDA-approved prescription pancreatic enzyme replacement therapy, not a conventional small-molecule drug with a simple active-ingredient equivalence pathway. Pancrelipase products contain complex mixtures of biological enzymes, and product substitution depends on formulation, enzyme activity, dosage form, and FDA approval status.
The main regulatory facts are:
| Regulatory issue |
VIOKACE status |
| Active ingredient |
Pancrelipase |
| FDA indication |
Exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy |
| Dosage form |
Immediate-release tablet |
| PPI requirement |
Yes |
| Approved strengths |
10,440, 20,880, and 41,760 USP lipase units |
| Applicant/marketer |
AbbVie, following the Forest Laboratories, Actavis, Allergan, and AbbVie corporate succession |
| Pediatric labeling |
The principal approved indication is adult-focused |
| Regulatory pathway |
NDA product |
| Biosimilar pathway |
Not applicable |
VIOKACE is not a biosimilar. Biosimilar concepts apply to biological products regulated under the Public Health Service Act. Pancrelipase products are regulated as drug products, but their complex enzyme composition makes direct generic substitution more difficult than substitution for a conventional tablet containing a single chemically defined molecule.
How does VIOKACE compare with CREON and other pancreatic enzyme products?
VIOKACE competes in the pancreatic enzyme replacement therapy market but has a distinct formulation profile.
| Product |
Manufacturer or marketer |
Dosage form |
Release profile |
PPI required by label |
Commercial position |
| VIOKACE |
AbbVie |
Tablet |
Immediate release |
Yes |
Niche product |
| CREON |
AbbVie |
Delayed-release capsule |
Enteric coated |
No routine PPI requirement |
Category leader |
| ZENPEP |
Nestlé Health Science |
Delayed-release capsule |
Enteric coated |
No routine PPI requirement |
Major competitor |
| PERTZYE |
Nestlé Health Science |
Delayed-release capsule |
Enteric coated |
No routine PPI requirement |
Specialist competitor |
| PANCREAZE |
Vivus |
Delayed-release capsule |
Enteric coated |
No routine PPI requirement |
Smaller competitor |
CREON has the strongest commercial position because it is widely used across cystic fibrosis, chronic pancreatitis, pancreatectomy, and other causes of exocrine pancreatic insufficiency. Its delayed-release formulation reduces dependence on acid suppression and provides greater dosing flexibility.
VIOKACE can remain clinically relevant for patients who are already using acid suppression, patients stabilized on the product, and prescribers who prefer a tablet formulation. Its position is less favorable for new starts when clinicians prioritize a delayed-release product with simpler administration.
What is the financial trajectory of VIOKACE?
AbbVie does not disclose standalone VIOKACE revenue, units, gross margin, or operating profit. Public financial reporting groups VIOKACE within broader product and therapeutic-category disclosures, if reported at all. This prevents a reliable calculation of VIOKACE’s annual growth rate or contribution to AbbVie earnings.
The available financial picture is therefore indirect:
- AbbVie reports CREON as a recognizable product within its established products portfolio.
- VIOKACE is not separately identified as a material revenue line in AbbVie’s annual reports.
- The absence of separate reporting indicates that VIOKACE is commercially immaterial relative to AbbVie’s major immunology, oncology, aesthetics, and neuroscience products.
- VIOKACE’s economic value is more likely concentrated in portfolio retention, physician familiarity, and patient continuity than in material corporate revenue.
CREON’s reported growth and market scale provide a useful upper bound for the AbbVie pancreatic enzyme franchise, but CREON sales cannot be attributed to VIOKACE. Any estimate that assigns a specific percentage of CREON revenue to VIOKACE would be unsupported by public filings.
What market forces affect VIOKACE demand?
Rising diagnosis and treatment of exocrine pancreatic insufficiency
Demand for pancreatic enzyme replacement therapy is supported by chronic pancreatitis, pancreatic surgery, pancreatic cancer, cystic fibrosis, and other conditions that impair digestive enzyme production. Greater clinical recognition of exocrine pancreatic insufficiency can increase prescriptions across the category.
VIOKACE captures only part of that demand because the product’s indication and formulation are narrower than those of leading delayed-release products.
Product shortages and supply reliability
Pancreatic enzyme products have experienced periodic supply constraints. Demand growth, manufacturing complexity, porcine raw-material dependence, and quality-control requirements can create shortages or allocation pressure. Shortages can increase switching among products, but they do not automatically translate into durable VIOKACE share gains because each product has different enzyme concentrations and release characteristics.
Porcine raw-material dependence
VIOKACE relies on porcine-derived enzymes. Manufacturing requires consistent sourcing, purification, potency testing, and control of biological variability. These requirements create barriers to entry and can limit the number of credible manufacturers. They also expose the product category to livestock supply, quality, and manufacturing disruptions.
Formulation preference
The requirement to use VIOKACE with a proton-pump inhibitor is the main commercial disadvantage. It can increase pill burden, complicate medication reconciliation, and create tolerability or long-term acid-suppression concerns. Delayed-release products generally have a stronger value proposition for patients who do not otherwise need a PPI.
What patents protect VIOKACE and when does it lose exclusivity?
VIOKACE is based on pancrelipase, an established active ingredient. Its principal protection is therefore more likely to arise from formulation, manufacturing, dosage-form, regulatory, and trademark rights than from composition-of-matter exclusivity over pancrelipase itself.
The public commercial record does not establish a standalone, product-specific patent-expiration date that can be used as a reliable VIOKACE loss-of-exclusivity event. The FDA Orange Book remains the controlling source for current patent and exclusivity listings associated with NDA 022210. AbbVie’s public financial disclosures do not identify a VIOKACE patent cliff or quantify revenue at risk from a particular patent expiration.
The relevant intellectual-property barriers include:
- The immediate-release tablet formulation.
- Enzyme stabilization and potency-control processes.
- Manufacturing methods for porcine pancrelipase.
- Dosage and administration methods involving acid suppression.
- Trademark protection for the VIOKACE name.
- Regulatory complexity associated with demonstrating equivalence to a complex enzyme mixture.
These barriers can delay competition even where basic pancrelipase composition claims are unavailable or expired.
Are there Paragraph IV challenges or generic VIOKACE competitors?
A Paragraph IV certification could challenge an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. Publicly available commercial disclosures do not identify a material, active Paragraph IV litigation campaign directed specifically at VIOKACE comparable to the patent activity surrounding larger drug franchises.
The competitive risk is more likely to arise from:
- A product-specific generic pancrelipase tablet.
- A competing immediate-release pancrelipase formulation.
- Prescriber switching to delayed-release products.
- Supply disruptions that alter pharmacy and payer preferences.
- Reimbursement changes favoring lower-cost pancreatic enzyme products.
A generic launch would not automatically be therapeutically interchangeable with CREON, ZENPEP, PERTZYE, or PANCREAZE. Formulation and enzyme-release differences would remain commercially important.
What patent litigation and settlement agreements affect VIOKACE?
No major publicly disclosed patent-litigation event or settlement agreement has been identified as a principal market driver for VIOKACE. The absence of a reported case does not create a guaranteed barrier to future entry. It indicates that VIOKACE has not generated the level of litigation visibility associated with high-revenue products facing multiple abbreviated new drug application filings.
Litigation risk would increase if a generic applicant filed an ANDA with a Paragraph IV certification against listed VIOKACE patents. The commercial impact would depend on the number of claims, the scope of any 30-month stay, the FDA’s tentative approval status, and whether the generic product matched VIOKACE’s immediate-release tablet formulation.
What generic launch scenarios exist for VIOKACE?
Base case: continued niche sales
The most likely near-term scenario is continued availability with stable or modestly declining demand. AbbVie can maintain VIOKACE for established patients while CREON remains the company’s primary pancreatic enzyme product.
Upside case: supply-driven switching
If competing delayed-release products face sustained shortages, VIOKACE could gain temporary prescriptions, particularly among patients already taking a PPI. The effect would likely be limited by clinical preference and formulation differences.
Downside case: gradual migration to delayed-release products
New prescribing may continue to shift toward CREON and other enteric-coated products. This would reduce VIOKACE’s share without requiring a generic launch.
Generic-entry case
A successful generic immediate-release pancrelipase tablet could pressure price and payer coverage. The impact would be greatest if the generic obtained a therapeutically substitutable rating and secured broad commercial distribution.
How strong is the VIOKACE patent estate?
VIOKACE has a moderate commercial barrier profile but not the characteristics of a high-value, composition-of-matter-protected franchise. The active ingredient is established, the market includes multiple pancrelipase products, and the product’s differentiation is primarily formulation and administration-based.
Its practical defenses are stronger than its apparent molecule-level exclusivity because:
- Pancrelipase manufacturing is technically demanding.
- Enzyme potency must be controlled across multiple activities.
- Raw-material sourcing is specialized.
- Product-specific clinical and regulatory requirements complicate substitution.
- The installed patient base creates switching friction.
Its weaknesses are equally clear:
- The PPI requirement limits convenience.
- AbbVie does not report a material standalone revenue stream.
- Delayed-release products have broader prescribing appeal.
- A product-specific generic could create price pressure if approved.
What is the geographic coverage and international opportunity?
VIOKACE’s commercial opportunity is concentrated in the United States, where the brand has FDA approval and established reimbursement pathways. International growth is constrained by country-specific registration, enzyme-unit labeling, reimbursement rules, and competition from locally available pancrelipase products.
The product’s immediate-release design may also face greater resistance outside the United States where delayed-release pancreatic enzyme products are well established. International expansion would require evidence that the tablet-plus-PPI regimen offers a meaningful clinical or economic advantage.
Key Takeaways
- VIOKACE is an FDA-approved immediate-release pancrelipase tablet for adults with exocrine pancreatic insufficiency caused by chronic pancreatitis or pancreatectomy.
- The product must be used with a proton-pump inhibitor, which limits convenience relative to CREON and other delayed-release products.
- AbbVie does not separately disclose VIOKACE revenue, making product-level financial modeling unavailable from public filings.
- CREON is the principal commercial asset in AbbVie’s pancreatic enzyme portfolio.
- VIOKACE’s strongest barriers are manufacturing complexity, porcine enzyme sourcing, regulatory requirements, and patient continuity.
- No major publicly disclosed Paragraph IV campaign, patent settlement, or VIOKACE-specific patent cliff is an established market driver.
- The principal commercial risk is gradual migration to delayed-release products rather than an immediately visible patent-driven generic event.
- A future generic immediate-release pancrelipase product could create price pressure, but substitution would depend on formulation and FDA approval details.
Frequently Asked Questions
Is VIOKACE still available in the United States?
VIOKACE remains an FDA-approved prescription product marketed by AbbVie. Availability can vary by wholesaler, pharmacy, and supply conditions.
Is VIOKACE interchangeable with CREON?
No. VIOKACE is an immediate-release tablet that must be taken with a proton-pump inhibitor, while CREON is a delayed-release capsule. Dosing and administration are product-specific.
Does VIOKACE have a biosimilar competitor?
No. Biosimilar regulation does not apply to VIOKACE because it is a pancrelipase drug product rather than a biologic regulated through the biosimilar pathway.
Why does VIOKACE require a proton-pump inhibitor?
VIOKACE is not enteric coated. Acid suppression helps protect the enzymes from gastric degradation and supports delivery of active enzymes to the small intestine.
Is VIOKACE financially material to AbbVie?
Public filings do not identify VIOKACE as a separately material revenue contributor. AbbVie’s pancreatic enzyme economics are dominated by the broader CREON franchise, while VIOKACE appears to occupy a smaller niche position.
References
- AbbVie Inc. (2024). 2023 annual report. https://investors.abbvie.com
- AbbVie Inc. (2025). 2024 annual report. https://investors.abbvie.com
- U.S. Food and Drug Administration. (2023). VIOKACE prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024). Drug shortages and pancreatic enzyme replacement products. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
